|
|
 | | | |
- close
- close
- close
- close
Ranbaxy Laboratories Ltd |
The Hindu Business Line
1 hr ago
Comment
The European Commission today imposed a fine of €146 million on nine pharma companies, including Ranbaxy Laboratories, for delaying market entry of cheaper generic versions of Danish company Lundb...
The Economic Times
6 hrs ago
Comment
"If there are concerns on stocks like Ranbaxy or Cipla, they are few and far between."
The Hindu Business Line
Jun 18
Comment
Non-compliance is far more costly than compliance. D. G. SHAH, SECRETARY-GENERAL, INDIAN PHARMACEUTICAL ALLIANCE
The Economic Times
Jun 18
Comment
Ranbaxy Laboratories, which has been in a downward trajectory for the past few weeks, plunged over 6% to hit a new 4-year low of Rs 342.75.
The Economic Times
Jun 18
Comment
All the sectoral indices except IT and metals ended in the red with capital goods, banks and oil & gas leading the decline.
The Economic Times
Jun 18
Comment
Ranbaxy Laboratories Ltd is a ‘SELL’ call with a target of Rs 343 and a stop loss of Rs 370.
The Hindu Business Line
Jun 17
Comment
Supreme Court will hear on June 24 a petition seeking probe against Ranbaxy Laboratories Ltd for allegedly manufacturing and selling adulterated medicines.
A bench of justices A K Patnaik...
The Economic Times
Jun 17
Comment
"Ranbaxy Laboratories Ltd is a ‘SELL’ call with a target of Rs 345 and a stop loss of Rs 375."
Wall Street Journal
Jun 14
Comment
Ranbaxy, Teva and other generic-drug makers are coming to grips with a drop in blockbuster brand-name medicines going off patent. One strategy: selling brand-name medicines.
The Hindu Business Line
Jun 14
Comment
"Scrutiny has always been there and the validation process is already stringent. But the frequency of inspection by regulatory agencies may increase. And there may be more surprise checks."
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
